Adenocarcinoma of Lung Clinical Trial
Official title:
Preoperative Evaluation of High-resolution Computed Tomography to Predict Pathologic Tumor Invasion in Ground-glass Opacity Featured Lung Adenocarcinoma
NCT number | NCT04165759 |
Other study ID # | PRSHRCT |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 18, 2019 |
Est. completion date | July 1, 2021 |
Verified date | July 2023 |
Source | Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1008). It aims to evaluate the correlation between radiological diagnosis based on HRCT and pathological invasiveness.Investigators observe the radiological features and the correlation with the postoperative pathological findings.
Status | Completed |
Enrollment | 620 |
Est. completion date | July 1, 2021 |
Est. primary completion date | April 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 85 Years |
Eligibility | Inclusion Criteria: (1) GGNs on HRCT scan; (2) clinical stage IA; (3) simultaneously no more than three nodules; (5) Age ranging from 15 to 85 years. Exclusion Criteria: (1) pathologically confirmed non-adenocarcinoma; (2) patients who did not receive surgery. |
Country | Name | City | State |
---|---|---|---|
China | Fudan University Cancer Center | Shanghai | Shanghai |
China | Fudan University Shanghai Cancer Center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Fudan University | Fujian Medical University Union Hospital, Jiangdu People's Hospital, Yangzhou, Shandong First Medical University Affiliated Liaocheng Second Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity | Diagnostic sensitivity of pathologic tumor invasion evaluated by HRCT | Pathologic reports were available, usually 1 month after surgery | |
Secondary | Value of radiologic parameters for tumor invasion | The receiver operating characteristic curve (ROC curve) and the area under the ROC curve (AUC) of the invasion prediction model based on radiologic parameters. | Pathologic reports were available, usually 1 month after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04122833 -
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
|
||
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04027946 -
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Not yet recruiting |
NCT05079022 -
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
|
Phase 1/Phase 2 | |
Completed |
NCT02616211 -
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
|
||
Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
Recruiting |
NCT05550961 -
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
|
||
Active, not recruiting |
NCT05292859 -
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
|
||
Not yet recruiting |
NCT05565677 -
Prognostic Value of Lung Cancer MicroAnatomy in 3D
|
||
Completed |
NCT05252676 -
Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011)
|
||
Recruiting |
NCT03838588 -
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
|
||
Recruiting |
NCT04105270 -
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
|
Phase 2 | |
Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
Completed |
NCT00073398 -
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04770688 -
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
|
Phase 1/Phase 2 | |
Completed |
NCT04086680 -
The Detection of EGFR Mutations in Liquid Based Cytology Samples
|
||
Completed |
NCT01362790 -
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06299163 -
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03298763 -
Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT02804646 -
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
|
Phase 4 |